Watch APRE. Know when insiders buy.
One email the day a filing lands. Free.
APRE
Aprea Therapeutics, Inc.
0.79
−0.01 −1.49%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $10MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$12.3MNET CASH —52W 0.59 – 1.65SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$4M | −$3.6M | — | -0.07 | −$3.3M | — | — | Aug 12 |
| Q1 2026 · Mar 31 | — | — | — | −$3.4M | −$3.3M | — | -0.22 | −$2.8M | — | — | Aug 12 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.6M | −$2.5M | — | -0.28 | −$3M | — | — | Mar 16 |
| Q3 2025 · Sep 30 | — | — | — | −$3.1M | −$3M | — | -0.47 | −$3.2M | — | — | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$3.4M | −$3.2M | — | -0.53 | −$3.1M | — | — | Aug 12 |
| Q1 2025 · Mar 31 | — | — | — | −$4.1M | −$3.9M | — | -0.66 | −$3.6M | — | — | Aug 12 |
| Q4 2024 · Dec 31derived | — | — | — | −$3.2M | −$2.9M | — | -0.47 | −$3.5M | $0 | −$3.5M | Mar 16 |
| Q3 2024 · Sep 30 | — | — | — | −$4.1M | −$3.8M | — | -0.64 | −$2.5M | $0 | −$2.5M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$3.8M | −$3.5M | — | -0.58 | −$3.6M | $8K | −$3.6M | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$3.1M | −$2.8M | — | -0.67 | −$3.9M | $8K | −$3.9M | Nov 12 |
| Q4 2023 · Dec 31derived | — | — | — | −$3.7M | −$3.4M | — | -0.92 | −$3.7M | $7K | −$3.7M | Mar 25 |
| Q3 2023 · Sep 30 | — | — | — | −$3.5M | −$3.2M | — | -0.86 | −$2.2M | — | — | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$13.2M | −$12.6M | — | -1.93 | −$12.9M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$14.3M | −$13M | — | -2.35 | −$13.6M | $15K | −$13.6M | — | — |
| FY2023 · to Dec 31 | — | — | −$15.5M | −$14.3M | — | -3.95 | −$12.2M | $93K | −$12.3M | — | — |
| FY2022 · to Dec 31 | — | — | −$113.4M | −$112.7M | — | -67.99 | −$25M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$37.4M | −$37.1M | — | -34.88 | −$37.7M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | — | −$53.5M | — | -50.61 | −$41.8M | $26K | −$41.8M | — | — |
Every number comes from Aprea Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.